Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,855 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Condition Clear all
Completed Phase 2Phase 3 Interventional

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

NCT01741194
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AC-1204, Placebo
Drug
Lead sponsor
Cerecin
Industry
Eligibility
66 Years to 90 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 23, 2026, 11:38 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022
View directory record Official record
Conditions
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Interventions
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
8
States / cities
Chandler, Arizona • Tucson, Arizona • Cerritos, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Not applicable Interventional Results available

Home-based Leg Heat Therapy

NCT03763331
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Control/Sham Treatment, Heat Therapy
Device
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 23, 2026, 11:38 AM EDT
Enrolling by invitation Not applicable Interventional

NAD Supplementation in Parkinson's Disease

NCT07703137
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Nicotinamide Riboside (NR), Oral placebo capsules
Dietary Supplement
Lead sponsor
University of Oklahoma
Other
Eligibility
55 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Not applicable Interventional

Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study

NCT04421339
View directory record Official record
Conditions
Huntington Disease
Interventions
Melatonin, Placebo
Dietary Supplement · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder

NCT01052077
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
OPC-34712, Placebo, ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Arcadia, California • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 23, 2026, 11:38 AM EDT
Terminated Not applicable Interventional

To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease

NCT02649075
View directory record Official record
Conditions
Crohn's Disease
Interventions
Serum-derived Bovine Immunoglobulin / Protein Isolate, Placebo
Other
Lead sponsor
Entera Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
North Little Rock, Arkansas • Hollywood, Florida • Winter Park, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Oct 23, 2026, 11:38 AM EDT
Terminated Phase 2 Interventional Results available

Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease

NCT00532883
View directory record Official record
Conditions
Hemoglobin SC Disease
Interventions
Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

NCT06138795
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD2389, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Phase 2 Interventional

Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00671073
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Oglemilast, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
40 Years to 80 Years
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 23, 2026, 11:38 AM EDT
Recruiting Phase 2 Interventional

Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD

NCT06194851
View directory record Official record
Conditions
Post-Traumatic Stress Disorder (PTSD)
Interventions
Oxytocin nasal spray, Saline nasal spray, Brief Cognitive-Behavioral Conjoint Therapy
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancing Medication-based Analgesia in Humans

NCT02901275
View directory record Official record
Conditions
Pain, Cannabis, Opioid Use, Unspecified
Interventions
Within-subject test of blinded study medications
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT00365300
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
pantoprazole, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
28 Days to 11 Months
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Not applicable Interventional

The Effect of Dietary Nitrates on Physical Performance and Vascular Function in Chronic Kidney Disease

NCT04103736
View directory record Official record
Conditions
Kidney Disease, Chronic, Endothelial Dysfunction
Interventions
Beet It Sport Shot, Nitrate-depleted placebo
Dietary Supplement
Lead sponsor
University of Delaware
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Not applicable Interventional Results available

Erythromycin in Parkinson's Disease

NCT02005029
View directory record Official record
Conditions
Parkinson's Disease, Levodopa
Interventions
Erythromycin, placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

NCT00400153
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg), Placebo via corresponding inhaler for blinding purposes
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
87
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)

NCT03385239
View directory record Official record
Conditions
Hypertriglyceridemia, Cardiovascular Diseases
Interventions
ISIS 678354, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Cottonwood, Arizona • Little Rock, Arkansas • Carmichael, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 23, 2026, 11:38 AM EDT
Terminated Phase 2 Interventional Results available

A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression

NCT04423757
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
BI 1358894, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Phase 1 Interventional

A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode

NCT07549581
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
Interventions
SEP-380135, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

NCT00812565
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, octagam 10%
Drug · Biological
Lead sponsor
Octapharma
Industry
Eligibility
50 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hoboken, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 23, 2026, 11:38 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

NCT01467700
View directory record Official record
Conditions
Acute Depressive Episode
Interventions
Ramelteon SL, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
141
States / cities
Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).

NCT05128929
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Hymecromone (H01), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 23, 2026, 11:38 AM EDT
Completed Not applicable Interventional Results available

Individualized Response to Vitamin D Treatment Study

NCT02925195
View directory record Official record
Conditions
Characteristics That Modify the Response to Cholecalciferol Treatment
Interventions
Vitamin D3, Placebo
Dietary Supplement · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Evanston, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 23, 2026, 11:38 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease

NCT06531395
View directory record Official record
Conditions
Sjögrens Disease
Interventions
Abiprubart, Placebo
Drug
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
16
States / cities
Menifee, California • Poway, California • Whittier, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 23, 2026, 11:38 AM EDT